Hanmi Pharmaceutical Publishes 'CSR Report' Highlighting Sustainable Management Achievements

[Asia Economy Reporter Jihee Kim] Hanmi Pharmaceutical has published its latest CSR report detailing its sustainability management goals and achievements.

Hanmi Pharmaceutical announced on the 14th that it has published the "2020-21 CSR Report," prepared based on the GRI Standards, the international guidelines for sustainability reporting, and posted it on its official website. Since releasing the first CSR report in 2017, the first in the domestic pharmaceutical industry, Hanmi Pharmaceutical has issued reports annually, producing a total of four reports to date.

This CSR report was created under the theme of the core corporate values: "Creation, Innovation, and Challenge." The report covers Hanmi Pharmaceutical's efforts and achievements for sustainable development under themes such as ▲ R&D management for new challenges ▲ Customer-oriented mindset and customer satisfaction management ▲ Challenge toward trust and ethical management ▲ Respect for human value and talent management ▲ Healthy and safe workplaces and EHS management ▲ Mutual growth and win-win management.

Additionally, the report includes major sustainability management news from Hanmi Pharmaceutical in 2020, materiality assessments on sustainability topics, ESG activity outcomes, and the implementation results of the UN's SDGs (Sustainable Development Goals), concretizing the company's sustainability management achievements.

The third-party verifier of this report, the Korea Standards Association, stated, "Hanmi Pharmaceutical recognizes R&D as the sustainability and social responsibility of a pharmaceutical company and is advancing as a global pharmaceutical company through innovative drug creation and solid growth. Hanmi Pharmaceutical is demonstrating exemplary ESG management in the domestic pharmaceutical industry, and if it continues its challenging execution as it does now, it is expected to firmly establish its position as a leader in the sustainability field."

Woongsoo Woo, CEO of Hanmi Pharmaceutical, said, "Despite the COVID-19 pandemic situation last year, Hanmi Pharmaceutical achieved solid results by firmly strengthening its foundation based on unwavering R&D and sustainability management. We will continue to recognize R&D as the sustainability and social responsibility of a pharmaceutical company and realize Hanmi Pharmaceutical's vision toward becoming a pharmaceutical powerhouse."

This content was produced with the assistance of AI translation services.